What is CHRS stock price today?

Visit our real-time dashboard for the current CHRS stock price and live market data.

Is CHRS stock going up or down today?

CHRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CHRS stock now?

The decision to buy CHRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CHRS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CHRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CHRS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CHRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CHRS's P/E ratio?

P/E ratio data for CHRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CHRS's market cap?

CHRS (Coherus BioSciences Inc) has a market capitalization of $0.22 billion, making it a small-cap stock.

What is CHRS's price to book ratio?

Price-to-book ratio for CHRS is available on our dashboard along with other valuation metrics.

Does CHRS pay dividends?

CHRS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CHRS's dividend yield?

CHRS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CHRS stock a good long-term investment?

CHRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CHRS's revenue growth rate?

Revenue growth data for CHRS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CHRS are available on our dashboard with complete income statement analysis.

What are the risks of investing in CHRS?

Key risks for CHRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CHRS compare to its competitors?

Compare CHRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CHRS's performance and positioning.

What is CHRS's stock price target for 2026?

Visit our prediction page for AI-powered price targets for CHRS with bull, base, and bear case scenarios.

What do analysts say about CHRS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CHRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CHRS's next earnings report?

CHRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CHRS - Coherus BioSciences Inc

NYSE * Healthcare * Biotechnology

$0.00

+$0.00 (+0.00%)

About Coherus BioSciences Inc

Coherus BioSciences Inc (CHRS) common stock

Price Chart

Loading chart...

CHRS Key Statistics

Market Cap

$223.66M

How CHRS Compares to Peers

CHRS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CHRS(This stock)	$223.66M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.67B	24.3	0%	0.0%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.0%	vs GILD
VRTXVertex Pharmaceuticals	$106.87B	29.7	0%	0.0%	vs VRTX
REGNRegeneron Pharmaceuticals	$59.10B	13.9	0%	0.0%	vs REGN
BIIBBiogen Inc	$29.33B	21.4	0%	0.0%	vs BIIB

Data Updated: July 20, 2026 at 6:56 PM EDT

Ready to invest in CHRS?

Commission-free trading available. Affiliate links.

CHRS Lician Score

5% confidence

4.0/10

Neutral

CHRS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates CHRSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

CHRS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for CHRS

Dashboard

Enter a ticker to analyze